{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:08:09Z","timestamp":1788761289647,"version":"build-2803163510"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Famotidine and omeprazole are widely used for the treatment of acid-related disorders in racehorses, and their combined administration is expected to provide complementary therapeutic effects due to their distinct mechanisms of action. However, their markedly different physicochemical properties present substantial challenges for simultaneous quantification in biological matrices. This study aimed to develop and validate complementary analytical strategies for the simultaneous determination of famotidine and omeprazole in equine plasma using high-performance liquid chromatography (HPLC) and ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS\/MS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Dual-platform analytical methods were developed, with sample preparation conditions tailored to the physicochemical properties of each compound. For HPLC analysis, the effects of sample preparation conditions on the chromatographic behavior and linearity of famotidine and omeprazole were evaluated. For UHPLC-MS\/MS analysis, a pH-neutral sample preparation strategy was established to preserve the stability of acid-labile omeprazole. The developed methods were validated according to relevant analytical validation parameters and subsequently applied to equine plasma samples collected following drug administration for pharmacokinetic evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In HPLC analysis, famotidine exhibited pH-dependent peak splitting associated with changes in its ionization state, which was resolved by acidifying the sample preparation solvent. Omeprazole showed limited solubility in aqueous environments, resulting in nonlinearity at higher concentrations; this was overcome by acidifying the plasma matrix, enabling quantification over 100-5,000 \u03bcg\/mL. Although the HPLC method effectively characterized the analytical behavior of both compounds, its sensitivity was insufficient for trace-level pharmacokinetic analysis. Therefore, a UHPLC-MS\/MS method was developed using pH-neutral sample preparation, enabling the simultaneous determination of omeprazole and its metabolite, omeprazole sulfone. The UHPLC-MS\/MS method achieved an LLOQ of 50 ng\/mL, representing an approximately 2,000-fold improvement in analytical sensitivity compared with HPLC. The developed methods demonstrated acceptable validation performance and were successfully applied to equine plasma samples, enabling the determination of concentration-time profiles and key pharmacokinetic parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The findings demonstrate that differences in the physicochemical properties and stability of famotidine and omeprazole require platform-specific sample preparation strategies for reliable simultaneous quantification. The complementary use of HPLC and UHPLC-MS\/MS provided both characterization of compound-specific analytical behavior and sensitive quantification of trace drug concentrations in equine plasma. This analytical framework may support pharmacokinetic studies of famotidine and omeprazole in equine models.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fvets.2026.1951616","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:32:59Z","timestamp":1788759179000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A complementary dual-platform analytical strategy for resolving matrix effects and stability limitations in bioanalysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Jang Mi","family":"Han","sequence":"first","affiliation":[{"name":"Institute of Digital Anti-Aging Healthcare, Inje University, Brain Korea 21 (BK21) FOUR Project","place":["Gimhae, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungho","family":"Yoon","sequence":"additional","affiliation":[{"name":"Equine Clinic, Jeju Stud Farm, Korea Racing Authority","place":["Jeju, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Beom","family":"Kwak","sequence":"additional","affiliation":[{"name":"Institute of Digital Anti-Aging Healthcare, Inje University, Brain Korea 21 (BK21) FOUR Project","place":["Gimhae, Republic of Korea"]},{"name":"College of Pharmacy, Inje University","place":["Gimhae, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1053\/bega.2001.0184","article-title":"Pharmacological and Pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the Practising physician","volume":"15","author":"Huang","year":"2001","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref2","first-page":"551","article-title":"An updated review of its Pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases","volume-title":"Drugs","author":"Langtry","year":"1989"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0889-8553(21)00047-9","article-title":"Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors","volume":"21","author":"Shamburek","year":"1992","journal-title":"Gastroenterol Clin N Am"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors","volume":"19","author":"Shin","year":"2013","journal-title":"J Neurogastroenterol Motil"},{"key":"ref5","first-page":"270","volume-title":"Gut","author":"Lind","year":"1983"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.1021\/ja049607w","article-title":"Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors","volume":"126","author":"Shin","year":"2004","journal-title":"J Am Chem Soc"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bcpt.13237","article-title":"Proton pump inhibitors: new mechanisms of action","volume":"125","author":"Tanus-Santos","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1097\/01.ccm.0000142398.73762.20","article-title":"Prevention of stress ulceration: current trends in critical care","volume":"32","author":"Daley","year":"2004","journal-title":"Crit Care Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0950-3528(93)90030-v","article-title":"Pharmacology of gastric acid inhibition","volume":"7","author":"Shamburek","year":"1993","journal-title":"Baillieres Clin Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000200098","article-title":"Omeprazole: pharmacology, pharmacokinetics and interactions","volume":"44","author":"Oosterhuis","year":"1989","journal-title":"Digestion"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1572-0241.1998.221_a.x","article-title":"Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors","volume":"93","author":"Peghini","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/j.1365-2036.2004.01949.x","article-title":"Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough","volume":"19","author":"Hammer","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.55544\/jrasb.4.1.4","article-title":"A comprehensive review on omeprazole: pharmacological effects and its adverse effects","volume":"4","author":"Kumar","year":"2025","journal-title":"J Res Appl Sci Biotechnol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1124\/dmd.113.051722","article-title":"Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions","volume":"41","author":"Shirasaka","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jphs.2019.03.001","article-title":"Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype","volume":"139","author":"Kamiya","year":"2019","journal-title":"J Pharmacol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2036.2005.02468.x","article-title":"Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-Oesophageal reflux disease","volume":"21","author":"Fujiwara","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/0016-5085(89)91489-3","article-title":"Suppression of nocturnal acid secretion with famotidine accelerates gastric ulcer healing","volume":"97","author":"McCullough","year":"1989","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00365528709090142","article-title":"Famotidine: a notable lack of drug interactions","volume":"22","author":"Humphries","year":"1987","journal-title":"Scand J Gastroenterol Suppl"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/00365520601026665","article-title":"Can famotidine and omeprazole be combined on a once-daily basis?","volume":"42","author":"Fandriks","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2746\/042516409X441910","article-title":"The prevalence and anatomical distribution of equine gastric ulceration syndrome (EGUS) in 201 horses in Denmark","volume":"41","author":"Luthersson","year":"2009","journal-title":"Equine Vet J"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1751-0813.2003.tb11469.x","article-title":"The prevalence and distribution of gastric ulceration in 345 racehorses","volume":"81","author":"Begg","year":"2003","journal-title":"Aust Vet J"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00480169.2007.36728","article-title":"Equine gastric ulcer syndrome in adult horses: a review","volume":"55","author":"Bell","year":"2007","journal-title":"N Z Vet J"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cveq.2009.04.013","article-title":"New perspectives in equine gastric ulcer syndrome","volume":"25","author":"Videla","year":"2009","journal-title":"Vet Clin North Am Equine Pract"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/jvim.13578","article-title":"European College of Equine Internal Medicine Consensus Statement--Equine Gastric Ulcer Syndrome in adult horses","volume":"29","author":"Sykes","year":"2015","journal-title":"J Vet Intern Med"},{"key":"ref25","first-page":"21","article-title":"Improved selectivity in detection of polar basic drugs by liquid chromatography-electrospray ionization mass spectrometry. Illustration using an assay method for the determination of famotidine in human plasma","volume-title":"J Chromatogr B Biomed Sci Appl","author":"Campanero","year":"2001"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/jms.176","article-title":"Determination of famotidine in low-volume human plasma by Normal-phase liquid chromatography\/tandem mass spectrometry","volume":"36","author":"Zhong","year":"2001","journal-title":"J Mass Spectrom"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/bmc.2873","article-title":"Quantitative determination of famotidine in human maternal plasma, umbilical cord plasma and urine using high-performance liquid chromatography-mass spectrometry","volume":"27","author":"Wang","year":"2013","journal-title":"Biomed Chromatogr"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3109\/00498254.2011.653655","article-title":"Different effects of proton pump inhibitors and famotidine on the Clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4","volume":"42","author":"Ohbuchi","year":"2012","journal-title":"Xenobiotica"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jchromb.2005.11.036","article-title":"Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry","volume":"831","author":"Hofmann","year":"2006","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e70114","DOI":"10.1002\/bmc.70114","article-title":"Novel LC-MS\/MS method for quantification of famotidine and metoprolol and application to pharmacokinetic interaction","volume":"39","author":"Xu","year":"2025","journal-title":"Biomed Chromatogr"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.talanta.2010.04.056","article-title":"A column-switching method for quantification of the enantiomers of omeprazole in native matrices of waste and estuarine water samples","volume":"82","author":"Barreiro","year":"2010","journal-title":"Talanta"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/s0039-9140(97)83117-7","article-title":"Spectrophotometric methods for the determination of omeprazole in bulk form and pharmaceutical formulations","volume":"44","author":"Sastry","year":"1997","journal-title":"Talanta"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"128779","DOI":"10.1016\/j.talanta.2025.128779","article-title":"Green synthesis of silver nanoparticles in deep eutectic solvent and their application in an electrochemical sensor for famotidine determination in pharmaceutical and biological samples","volume":"298","author":"Gomes-Junior","year":"2026","journal-title":"Talanta"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.talanta.2018.01.021","article-title":"Application of Polyacrylonitrile nanofibers decorated with magnetic carbon dots as a resonance light scattering sensor to determine famotidine","volume":"181","author":"Maleki","year":"2018","journal-title":"Talanta"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.talanta.2005.01.017","article-title":"Square wave adsorptive stripping Voltammetric determination of famotidine in urine","volume":"66","author":"Skrzypek","year":"2005","journal-title":"Talanta"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.talanta.2007.06.036","article-title":"Capillary zone electrophoresis method for the determination of famotidine and related impurities in pharmaceuticals","volume":"74","author":"Helali","year":"2008","journal-title":"Talanta"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jchromb.2013.01.020","article-title":"Comparative validations of non-aqueous capillary electrophoresis and high-performance liquid chromatography methods for the simultaneous determination of histamine H2 receptor antagonists in human urine","volume":"921","author":"Berzas Nevado","year":"2013","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jchromb.2004.12.039","article-title":"High-throughput screening of corticosteroids and basic drugs in horse urine by liquid chromatography-tandem mass spectrometry","volume":"825","author":"Leung","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jchromb.2016.06.046","article-title":"Study of the effect of CYP2C19 polymorphisms on omeprazole pharmacokinetics by utilizing validated LC-MS\/MS and real time-Pcr methods","volume":"1047","author":"Koukoula","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jchromb.2010.03.026","article-title":"Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS\/MS--a high throughput approach to evaluate drug-drug interactions","volume":"878","author":"Zhang","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00535-003-1240-6","article-title":"The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH","volume":"39","author":"Abe","year":"2004","journal-title":"J Gastroenterol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e5482","DOI":"10.1002\/bmc.5482","article-title":"Retention behaviour of analytes in reversed-phase high-performance liquid chromatography-a review","volume":"37","author":"Ganesh","year":"2023","journal-title":"Biomed Chromatogr"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.7897\/2230-8407.04407","article-title":"Hplc method development and validation: a review","volume":"4","author":"Sabir","year":"2016","journal-title":"Int Res J Pharm"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.3390\/app15041694","article-title":"The influence and compensation of environmental factors (pH, temperature, and conductivity) on the detection of chemical oxygen demand in water by UV-vis spectroscopy","volume":"15","author":"Li","year":"2025","journal-title":"Appl Sci"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1093\/clinchem\/4.6.452","article-title":"Buffer capacities of human blood and plasma","volume":"4","author":"Ellison","year":"1958","journal-title":"Clin Chem"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/chromsci\/bmw008","article-title":"Development and validation of a novel stability-indicating RP-HPLC method for the simultaneous determination of related substances of Ketoprofen and omeprazole in combined capsule dosage form","volume":"54","author":"Koppala","year":"2016","journal-title":"J Chromatogr Sci"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3797\/scipharm.1306-06","article-title":"Design of Experiment (DOE) utilization to develop a simple and robust reversed-phase HPLC technique for related substances' estimation of omeprazole formulations","volume":"81","author":"Manranjan","year":"2013","journal-title":"Sci Pharm"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"7294","DOI":"10.1039\/C9NJ00932A","article-title":"Identification and structural characterization of the stress degradation products of omeprazole using Q-Tof-LC-ESI-MS\/MS and NMR experiments: evaluation of the toxicity of the degradation products","volume":"43","author":"Shankar","year":"2019","journal-title":"New J Chem"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10337-025-04418-3","article-title":"Determination of omeprazole and its related impurities in bulk drug substance batches by a stability indicating HPLC method based on a short octyl fused core column","volume":"88","author":"Rathnasekara","year":"2025","journal-title":"Chromatographia"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4103\/0975-7406.80766","article-title":"Development and validation of a stability indicating method for the enantioselective estimation of omeprazole enantiomers in the enteric-coated formulations by high-performance liquid chromatography","volume":"3","author":"Vyas","year":"2011","journal-title":"J Pharm Bioallied Sci"},{"key":"ref51","first-page":"753","article-title":"Kinetics of omeprazole degradation in solid state","volume":"68","author":"Popielarz-Brzezinska","year":"2011","journal-title":"Acta Pol Pharm"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3109\/03639049509026660","article-title":"Stability of omeprazole solutions at various pH values as determined by high-performance liquid chromatography","volume":"21","author":"Mathew","year":"1995","journal-title":"Drug Dev Ind Pharm"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/jvp.12491","article-title":"Re-evaluation of the regulation of omeprazole in racehorses: an evidence-based approach","volume":"41","author":"Viljanto","year":"2018","journal-title":"J Vet Pharmacol Ther"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/pharmaceutics17020161","article-title":"Acid-neutralizing omeprazole formulation for rapid release and absorption","volume":"17","author":"Ramesh","year":"2025","journal-title":"Pharmaceutics"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00228-006-0251-7","article-title":"Absolute bioavailability and metabolism of omeprazole in relation to Cyp2c19 genotypes following single intravenous and Oral administrations","volume":"63","author":"Uno","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00007691-199003000-00010","article-title":"The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses","volume":"12","author":"Regardh","year":"1990","journal-title":"Ther Drug Monit"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1951616\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:33:01Z","timestamp":1788759181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1951616\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":56,"alternative-id":["10.3389\/fvets.2026.1951616"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2026.1951616","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1951616"}}